SCHEMBL8683588

SCHEMBL8683588

CCOC(=O)c1ccc2c(c1)C(c1ccccc1)(C(CC)Nc1ccccn1)N=N2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.44
▸ RAB9A P51151 4/20 0.44
▸ HTT P42858 2/20 0.43
▸ MAPT P10636 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ MEN1 O00255 4/20 0.36
▸ KMT2A Q03164 4/20 0.36
▸ TP53 P04637 2/20 0.35
▸ THRB P10828 2/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8683591 0.76 NPC1 (0.43) NPC1RAB9AHTTMAPTGAA
SCHEMBL8682249 0.71 NPC1 (0.41) NPC1RAB9AHTTMAPTGAA
SCHEMBL8684065 0.65 RAB9A (0.47) NPC1RAB9AHTTMAPTGAA
SCHEMBL23518343 0.64 MAPT (0.65) NPC1RAB9AHTTMAPTALDH1A1
SCHEMBL27974080 0.63 KDM4E (0.52) NPC1RAB9AHTTMAPTGAA
SCHEMBL8494757 0.63 KDM4E (0.52) NPC1RAB9AHTTMAPTGAA
SCHEMBL20027590 0.61 KDM4E (0.50) NPC1RAB9AHTTMAPTGAA
SCHEMBL304684 0.61 CA12 (0.49) NPC1RAB9AMAPTALDH1A1MEN1
SCHEMBL1568064 0.61 RAB9A (0.59) NPC1RAB9AHTTMAPTGAA
Hydrochloric Acid SCHEMBL27898270 0.61 LMNA (0.46) NPC1RAB9AHTTMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5760028-A TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-06-02 — — US disclosed
Send feedback